Novo Will Go After MACE Indication For Victoza Based On LEADER
This article was originally published in The Pink Sheet Daily
Positive cardiovascular outcomes data for Victoza were outlined at ADA, and Novo Nordisk said it plans to file an sNDA with FDA seeking a broad indication to include reduction in major adverse cardiac events (MACE). The indication is different than the one Lilly is pursuing for Jardiance.
Register for our free email digests: